ArticleFrontiers in oncology2023

FOXD1 is associated with poor outcome and maintains tumor-promoting enhancer-gene programs in basal-like breast cancer.

Kohei Kumegawa et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.